(PSCI 21-030) A Phase 1b/2, Randomized, Controlled, Open-Label Study Evaluating the Safety and Efficacy of ABBV-927 Administered in Combination With Modified FOLFIRINOX (mFFX) With or Without Budigalimab Compared to mFFX in Subjects With Untreated Metastatic Pancreatic Adenocarcinoma
A study evaluating the safety and efficacy of an investigational drug for persons with pancreas cancer
Study screening tests including a blood draw. Blood draws and questionnaires for 7 plus cycles consisting of Day 1, Day 3, Day 15, and Day 17 visits. Depending on the phase of the study and the treatment determined by the study doctor, study treatment may be given. Final visit 30 days after last dose of drug. The patient may be contacted 90 days after their last dose of study drug. They will be asked questions about how they are feeling and if they have had any changes in their medications. After they discontinue treatment, the patient may be contacted (every 8 weeks during the first year after treatment starts, or every 12 weeks thereafter) to follow up on their disease, including whether they have started any additional anti-cancer therapies.
prior surgery for pancreatic cancer